Could weak muscles mean higher bleeding risk for seniors on blood thinners?
NCT ID NCT07173075
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looks at whether older adults (70+) with low muscle mass are more likely to have serious bleeding while taking common blood thinners (apixaban or rivaroxaban). Researchers will compare muscle mass in 110 patients who had a bleeding event with those who did not. The goal is to see if simple muscle measurements can help predict bleeding risk.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could help doctors identify elderly patients at higher risk of bleeding while on blood thinners, potentially leading to safer prescribing.
What could go wrong
This is an observational study with only 110 participants, so it cannot prove cause and effect. Results may not apply to all older adults or other blood thinners.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOPENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU de Clermont-Ferrand
Clermont-Ferrand, 63000, France
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••